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binding to its physiological ligand hepatocyte growth factor
(HGF) results in increased cell proliferation and cell motility,
processes critical for embryonic development, tissue regeneration, and homoeostasis (for review, see Ref. 1). Persistent cMet
signaling occurs in many human cancers, correlating closely
with early stage invasion, dissemination, and metastases (for
review, see Refs. 1 and 2). Once activated by ligand binding,
cMet is normally endocytosed exclusively through clathrincoated pits (3, 4) and then inactivated by lysosomal degradation
(3, 5). Although several mechanisms likely contribute to sustained cMet signaling in cancer (6 –12), dysregulated receptor
internalization and degradation have recently emerged as novel
mechanisms for cMet-induced cell transformation and the
increased neoplastic growth of human tumors (13–16).
Endocytic studies on other RTKs, most notably the epidermal growth factor receptor (EGFR), suggest that modification
of the endocytic trafficking machinery by the activated receptor
and/or its associated signaling molecules regulates receptor
internalization and degradation. For example, the signaling
adaptor Grb2 has been shown to function as an important initiator of EGFR endocytosis (17–20). Small interfering RNA
(siRNA)-mediated depletion of Grb2 and overexpression of
Grb2-SH3 mutants deficient in binding downstream signaling
molecules blocks the recruitment of EGFR into clathrin-coated
pits and subsequent receptor internalization, with negligible
effects on the downstream activation of mitogen-activated protein kinase or phosphatidylinositol 3-kinase (19). Grb2 functions to regulate EGFR internalization through the recruitment
of the E3 ubiquitin ligase Cbl (20 –22). However, it remains
unclear if the requirement for Grb2 on EGFR endocytosis is
mediated solely through interactions with Cbl, functions at the
level of EGFR ubiquitination, involves additional Grb2dependent interactions, or extends to other RTKs.
cMet and the EGFR are prototypic members for distinct RTK
subfamilies and as such exhibit unique structural and functional characteristics. In contrast to the EGFR, cMet is a heterodimer composed of an extracellular ␣ chain that is disulfidelinked to a transmembrane ␤ chain that contains cytoplasmic
tyrosine kinase activity (23–25). The extracellular domain of
cMet contains a distinctive ␤-propeller fold that mediates
ligand binding (26). Ligand binding induces the autophosphorylation of cMet and EGFR at multiple tyrosines in their respective C-terminal regions enabling the recruitment and subsequent activation of shared downstream adaptor and signaling
molecules. The EGFR possesses six tyrosine transphosphorylation sites dispersed throughout the C-terminal region (for
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Lysosomal degradation of the receptor-tyrosine kinase cMet
requires receptor ubiquitination by the E3 ubiquitin ligase Cbl followed by clathrin-dependent internalization. A role for Cbl as an
adaptor for cMet internalization has been previously reported.
However, the requirement for Cbl ubiquitin ligase activity in this
process and its mode of recruitment to cMet has yet to be determined. Cbl can directly bind cMet at phosphotyrosine 1003 or indirectly via Grb2 to phosphotyrosine 1356 in the multisubstrate
binding domain of cMet. The direct binding of Cbl with cMet is
critical for receptor degradation and not receptor internalization.
Here we show a strict requirement for Grb2 and the ubiquitin ligase
activity of Cbl for cMet endocytosis. Receptor internalization was
impaired by small interfering RNA depletion of Grb2, overexpression of dominant negative Grb2 mutants, and point mutations in
the cMet multisubstrate docking site that inhibits the direct association of Grb2 with cMet. The requirement for Grb2 was specific
and did not involve the multiadaptor Gab1. cMet internalization
was impaired in cells expressing an ubiquitin ligase-deficient Cbl
mutant or conjugation-deficient ubiquitin but was unaffected in
cells expressing a Cbl mutant that is unable to bind cMet directly.
Expression of a Cbl-Grb2 chimera rescued impaired cMet endocytosis in cells depleted of endogenous Grb2. These results indicate
that the ubiquitin ligase activity of Cbl is critical for clathrin-dependent cMet internalization and suggest a role for Grb2 as an
intermediary linking Cbl ubiquitin ligase activity to this process.

cMet Uptake Requires Grb2 and Cbl Ubiquitin Ligase Activity

EXPERIMENTAL PROCEDURES
Reagents, Antibodies, and Plasmids—All general reagents
were obtained from Fisher or Sigma-Aldrich unless indicated otherwise. Recombinant human HGF was purchased
from PeproTech Inc, Rocky Hill, NJ. EZ-link sulfo-NHS-SSbiotin, D-salt dextran, and spin columns were purchased from
Pierce. Texas Red-labeled-transferrin (Tfn) and antibody labeling kits were obtained from Invitrogen. The following antibodies were purchased as indicated; Shc (BD Biosciences), antihuman HGF (R&D Systems Inc, Minneapolis, MN), transferrin
receptor (Invitrogen), anti-␤-actin and anti-phosphotyrosine
clone PY-20 (Sigma-Aldrich), ubiquitin (P4D1), Cbl (C-15),
Grb2 (C-23), cMet C-12, and cMet C-28 (Santa Cruz Biotechnologies), anti-Gab1 CT, phospho-Met Tyr-1234, Tyr-1235
(UpState Biotechnology), Gab1, phospho-Gab1, c-Jun N-terminal kinase (JNK), phospho-JNK, p42/p44 MAPK, phospho
p42/p44, MEK (mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase), and phospho-MEK (Cell Signaling Technology), the monoclonal GFP antibody (JL-8) (BD
Biosciences Clontech), peroxidase-conjugated goat anti-mouse
immunoglobulin G (IgG) and goat anti-rabbit IgG (Jackson
ImmunoResearch Laboratories, Inc.), and Alexa488 or Alexa594JUNE 8, 2007 • VOLUME 282 • NUMBER 23

labeled goat anti-mouse, anti-rabbit, or anti-rat secondary antibodies (Invitrogen). A pLXSN plasmid encoding wild type (wt)cMet was previously reported (44). pLXSN plasmids encoding
the full-length Met mutants N1358H and Y1349F,Y1356F were
generously provided by Pascal Peschard and Morag Park
(McGill University). The K1110A allele encodes a Met receptor
lacking kinase activity (45, 46). The K1110A mutation was generated through a PCR-based SOEing approach (47) using wild
type cMet cDNA as a template, Pfu DNA polymerase, and the
primers 5⬘-CAAGCTAGCCACAGCACAGTG-3⬘, 5⬘-CCCATCCTAACTAGTGGGGAC-3⬘, 5⬘-CACTGTGCTGTGGCTAGCTTG-3⬘, and 5⬘-GCTCTAGAACTAGTGGATCCC-3⬘.
The final ⬃1.3-kilobase PCR product was subcloned between
the SpeI and XcmI sites of pLXSN-Met-wt, resulting in a fulllength Met gene with the K1110A mutation and verified by
DNA sequencing. The various Met alleles were subcloned from
the plasmid pLXSN into the murine stem cell virus vector
pMSCVpuro (BD Biosciences) for retroviral-mediated transfection in the target cell lines. pYFP-N1 plasmids encoding
Grb2 and Grb2-mSH3 were kindly provided by Lawrence
Samelson (National Institutes of Health) (48). The pEGFP plasmids encoding Cbl, Cbl-SH2, Cbl-SH2/R86A, Grb2-SH2,
and Grb2/R86A were kindly provided by Alexander Sorkin
(University of Colorado Health Sciences Center) (17, 22).
pcDNA3-Myc-UbR and pcDNA3-Myc-UbRL8A/I44A were
kind gifts from Inger Madshus (Norwegian Radium Hospital)
(18). Plasmids encoding hemagglutinin-tagged Cbl (wt), 70ZCbl, and Cbl-G306E were kindly provided by Jannie Borst (The
Netherlands Cancer Institute) (20).
Cell Lines—The H10 cell line derived from kidney epithelial
cells from embryos of cMet null ⫺/⫺ mice (49) was a generous
gift of Dr. Lloyd Cantley (Yale University School of Medicine).
Polyclonal H10 cell lines expressing cMet alleles were generated by retroviral transfection essentially as described (50),
except that 1–5 g/ml puromycin was used for selection, and
limiting dilution was not performed. Cell lines were analyzed
for cMet expression by Western blotting with the anti-cMet
antibody DL-21 (Upstate Biotechnology), and those cell lines
that exhibited similar cMet levels were chosen for further analysis. The parental H10 cMet null ⫺/⫺ cell line was maintained
in Dulbecco’s modified Eagle’s medium/F-12(1:1) with 10%
fetal bovine serum. H10 derivatives stably expressing wild type
or mutant cMet alleles were grown in the same medium containing 5 g/ml puromycin. Human mammary epithelial cells
(T47D) stably expressing full-length human cMet (T47D/
cMet) were a generous gift of Morag Park (McGill University)
and were maintained in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum supplemented with 400
g/ml G418.
siRNAs and Cell Transfections—For siRNAs depletion studies, cells were grown on coverslips in 60-mm plates and transfected with SmartpoolsTM containing four siRNA duplexes for
Gab1, Grb2, Shc, or a control siRNA using Lipofectamine 2000
reagent (Invitrogen). Typically each coverslip of cells was transfected with 200 pmol of siRNA and 8 l of Lipofectamine 2000.
T47D/cMet cells were routinely cultured on coverslips coated
with 100 g/ml polylysine before experimentation. All experiments were routinely performed 72 h after siRNA transfection.
JOURNAL OF BIOLOGICAL CHEMISTRY
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review, see Ref. 27), whereas cMet contains two key tyrosine
phosphorylation sites at positions 1349 and 1356 in a unique
multisubstrate-docking site, that function to concomitantly
activate multiple downstream signaling pathways (28, 29). In
contrast to cMet, which contains one binding site for the signaling adaptor Grb2 at phosphotyrosine 1356 (28, 30), Grb2
binds EGFR directly at two sites (31). Moreover, Grb2 appears
to play a minor role in signaling events downstream of ligand
activated cMet in vivo (32–34) when compared with the EGFR
(34). The adaptor protein Gab1 binds to two sites in the multisubstrate-docking site of cMet; directly at phosphotyrosine
1349 or indirectly via the adaptor Grb2 to phosphotyrosine
1356 (35–38). Gab1 recruitment is essential for the induction
of cell motility, branching morphogenesis, and the formation of crypts in three-dimensional matrices, hallmarks of
cMet signaling (29, 33, 39 – 41). Given these differences in
adaptor recruitment and biological activity, some differences may exist in the regulatory mechanisms controlling
cMet versus EGFR internalization.
The E3 ubiquitin ligase Cbl has been shown to mediate the
ubiquitination of ligand-activated cMet (4, 5, 14, 42, 43), receptor internalization (4), and degradation (13, 14). Cbl recruitment via its tyrosine kinase binding domain to phosphotyrosine
1003 of cMet has been shown to contribute to receptor ubiquitination (13, 14, 42) and degradation in lysosomes (13, 14, 43).
Cbl has been shown to function as an adaptor important for
cMet internalization through clathrin-coated pits via the
recruitment of the endophilin-CIN85 complex (4). However,
a requirement for Cbl ubiquitin ligase activity and its mode
of recruitment for cMet internalization was not examined. In
this study we report that the ubiquitin ligase activity of Cbl is
important for clathrin-mediated cMet internalization. Moreover, Grb2 bound directly to the cMet multisubstrate docking
site acts as an intermediary for Cbl ubiquitin ligase activity in
these events.

cMet Uptake Requires Grb2 and Cbl Ubiquitin Ligase Activity
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analysis. Cell viability, as determined by the exclusion of propidium iodide, routinely exceeded 95%. 20,000 cells were analyzed for each sample in triplicate for each condition in each
experiment. The mean fluorescence intensity (MFI) of the cells
at each time point was analyzed and compared with a negative
control using control antibody only. The MFI values for each
condition were averaged, and the S.E. was calculated across all
experiments. The relative percentage of residual cell surface
cMet at each time point (tx) was calculated relative to the MFI of
cells without internalization (t0) as (MFI tx ⫺ MFI control antibody only/MFI t0 ⫺ MFI control antibody only) ⫻ 100.
InlB Labeling, Confocal Microscopy, and Analysis—The purification and labeling of recombinant His6-tagged InlB has been
described in detail elsewhere (3). For confocal microscopy cells
grown on coverslips were incubated in media containing 5.0
g/ml Alexa594-labeled Tfn with 100 ng/ml InlB or HGF for 10
min at 37 °C, then fixed immediately after each experiment
using 4% paraformaldehyde (Ted Pella Inc.) in PBS. Residual
paraformaldehyde was quenched using 50 mM NH4Cl/PBS, and
cells were then permeabilized with 0.05% (w/v) saponin (or
0.1% Triton X-100, PBS for HGF staining) for 20 min and then
blocked with 10% goat serum in PBS. All antibody dilutions
were performed in 5% goat serum, PBS with 0.05% saponin for
1 h. In studies staining for HGF, saponin was omitted from the
buffers. Coverslips were mounted and observed using a Zeiss
LSM 510 confocal microscope with a 63⫻ oil (1.4 NA) immersion objective. Samples were visualized with the 488- and
543-nm laser lines and emission filter sets at 505–530 nm for
YFP and Alexa488 detection or 585– 615 nm for Texas Red and
Alexa594 detection, respectively. Figure presentation was
accomplished in Adobe Photoshop Version 6.0. Quantification
of co localization and internal fluorescence intensity were
accomplished using Metamorph v5.0 (Molecular Devices) as
described previously (3). All pixel intensity levels were normalized relative to control values, expressed as a percentage ⫾ S.E.,
and differences were statistically verified by analysis of variance
using GraphPad Prism Software (GraphPad Software Inc.).

RESULTS
The Tyrosine Kinase Activity and the Docking Site Phosphotyrosines 1349 and 1356 of cMet Are Required for Ligand-induced Internalization—All of the known signaling cascades
downstream of activated cMet are mediated by autophosphorylation of two key tyrosines located at positions 1349 and 1356
in the novel multisubstrate docking site (28). To determine
whether autophosphorylation of these tyrosine residues is critical for cMet internalization, wt or mutant cMet was expressed
in cells immortalized from the kidneys of cMet null (⫺/⫺)
mice. These epithelial cMet⫺/⫺ cells undergo chemotaxis and
branching morphogenesis in response to EGF and transforming growth factor-␣ but not HGF, indicating that cMet signaling is specifically abrogated in these cells (49). We generated
several cell lines stably expressing moderate levels of wt or
mutant cMet, including tyrosine kinase-deficient K1110A
cMet (KinD-cMet) and the multisubstrate-docking site mutant
Y1349F,Y1356F (YF-cMet), which is deficient in Gab1 and
Grb2 binding. siRNA-mediated depletion of clathrin heavy
chain inhibited wt cMet internalization (supplemental Fig. S1),
VOLUME 282 • NUMBER 23 • JUNE 8, 2007
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Cell transfections using plasmids were performed as previously
described (3).
Immunoprecipitation and GST Pulldown Assays—For
immunoprecipitation (IP) studies cells were washed twice with
ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 8.2 mM Na2HPO4, 1.5
mM KH2PO4) and lysed on ice in radioimmune precipitation
assay buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA)
with protease inhibitors (2 g/ml aprotinin, 2 g/ml leupeptin,
2 g/ml pepstatin) and phosphatase inhibitors (10 mM NaF, 2
mM Na3VO4). Cell lysates were cleared by centrifugation at
12,000 ⫻ g at 4 °C, and then 500 –1000 g of each lysate was
incubated with 5 g of primary antibody overnight at 4 °C.
Antibody-protein complexes were precipitated with 50 l of
protein A/G-agarose solution (Pierce) by rotation at 4 °C for
4 h. The protein-beads complex were collected by centrifugation at 1000 ⫻ g for 5 min, washed with lysis buffer 3 times, and
then resuspended in SDS loading buffer and fractionated by
SDS/PAGE. For GST pulldown assays, the cell lysates were prepared in lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EDTA, 2 g/ml aprotinin, 2 g/ml leupeptin, 2 g/ml pepstatin, 10 mM NaF, 2 mM Na3VO4). Lysates
(0.5–1.0 mg of protein) were incubated with the appropriate
GST fusion proteins prebound to glutathione-Sepharose beads
(Sigma) overnight at 4 °C. Beads were washed three times in
lysis buffer followed by a final wash in 10 mM Tris-HCl, pH 7.4,
then analyzed by SDS/PAGE.
Cell Surface Biotinylation and Western Analysis—The biotinylation and receptor internalization assays were described
previously (3). Briefly, cells were surface-biotinylated at 4 °C for
30 min with EZ-link NHS-SS-biotin (Pierce). Surface-expressed proteins were isolated directly using streptavidin-agarose beads as described by the manufacturer (Pierce) and identified by Western analysis. Western analysis was performed
using ECL (GE Healthcare), and the resulting digitized blots
were quantified using AlphaEase Version 3.1.2 Software (Alpha
Innotech Corp.).
Flow Cytometry Analysis— cMet internalization from the
plasma membrane was measured by assaying the residual
amount of immunoreactive receptor accessible at the cell surface to a monoclonal antibody recognizing an extracellular
epitope. Briefly, cells grown to 80% confluence on 60-mm
dishes were sera-starved for 4 – 6 h and then stimulated with
100 ng/ml internalin B (InlB) at 37 °C under steady state conditions to drive cMet internalization. At the indicated times,
receptor endocytosis was terminated by placing the cells on ice.
The cells were immediately rinsed with ice-cold PBS, and residual surface-bound InlB was stripped using three consecutive
5-min ice-cold acid washes (Dulbecco’s modified Eagle’s
medium, pH 3.5). Cells were detached with PBS containing 5
mM EDTA and then resuspended in ice-cold FACS buffer (PBS
containing 2% fetal bovine serum). Cells were incubated with
anti-cMet antibody (AF276, R&D System, MN) in FACS buffer
at 4 °C for 1 h, washed 3 times with ice-cold FACS buffer, and
then incubated with Alexa488-conjugated secondary antibody
in FACS buffer at 4 °C for 30 min. After 3 ice-cold washes with
FACS buffer, the cells were analyzed using a FACS Canto flow
cytometer or fixed with 2% paraformaldehyde, PBS for later

cMet Uptake Requires Grb2 and Cbl Ubiquitin Ligase Activity
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FIGURE 1. cMet internalization requires phosphotyrosines 1349 and
1356. A, cMet signaling in stable cMet null (⫺/⫺) cells expressing wt, KinD, or
a mutant deficient in Grb2 and Gab1 binding (YF) was examined after incubation with (⫹) or without (⫺) 100 ng/ml InlB for 15 min at 37 °C by IP and
Western analysis (IB) for expression of total protein (cMet, Cbl), cMet ubiquitination (Ub) and phosphorylation (P-Met), and Cbl phosphorylation using the
anti-phosphotyrosine antibody PY20. The positions of molecular mass markers are indicated (kDa). B, pulldown (PD) surface biotinylation assays verified
that wt and mutant cMet were expressed at comparable levels on the cell
surface. C, Grb2 binding was detected in null (⫺/⫺) cells stably expressing wt
but not mutant cMet in response to treatment with 100 ng/ml InlB. D, Gab1
was phosphorylated in response to treatment with (⫹) 100 ng/ml InlB in cells
expressing wt but not mutant cMet. E, cMet null (⫺/⫺) cells expressing wt or
the indicated cMet mutants were left untreated (0 min) or treated with 100
ng/ml InlB for 5, 10, or 20 min at 37 °C. The cells were chilled to 4 °C, and cMet
on the cell surface was specifically labeled with anti-cMet antibody and quantified by flow cytometry. Results represented the mean fluorescent intensities
normalized to untreated cells under each experimental condition from triplicate experiments. Bars represent the means for data across all experiments
with S.E.

firm that the recruitment of Gab1 and Grb2 to cMet is disrupted in the YF- and KinD-cMet mutants but not in cells
expressing wt cMet.
We next examined ligand-induced internalization of wt and
mutant cMet using a flow cytometric method that measures the
amount of immunoreactive receptor remaining on the cell surface after ligand treatment. Briefly, cMet null cells stably
expressing wt or mutant cMet were incubated in the presence
or absence of InlB (100 ng/ml) for increasing periods of time at
37 °C. After incubation, the cells were then chilled on ice to
prevent further receptor trafficking, and cMet remaining on the
cell surface was labeled specifically with a cMet-specific antibody under non-permeabilized conditions. Flow cytometry
analysis was then used to quantify the relative number of immunoreactive receptors remaining on the cell surface under these
conditions (Fig. 1E). All cell populations expressed similar levels of surface cMet under control conditions (i.e. no receptor
internalization at 4 °C), consistent with their initial selection
based on similar levels of cell surface receptor expression (data
not shown). As expected, reduced levels of wt cMet were
detected on the cell surface relative to cells incubated in the
absence of InlB, consistent with ligand induced-receptor internalization. In contrast to wt cMet, higher cell surface levels of
JOURNAL OF BIOLOGICAL CHEMISTRY
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confirming that cMet internalization is clathrin-dependent in
these cells, consistent with our previous studies using T47D/
cMet and Vero cells (3).
We previously reported that the soluble form of the InlB
protein of Listeria monocytogenes mimics HGF-induced cMet
internalization and degradation (3). In addition to being presented as a soluble protein, InlB is also found anchored to the
cell surface of bacteria (51). The surface-anchored form of InlB
mediates bacterial uptake into host cells (5), whereas soluble
InlB is thought to modulate host transcriptional responses (52,
53). We previously reported that HGF and soluble InlB are
internalized with cMet via a clathrin-dependent mechanism
(3). Interestingly, evidence indicates that the internalization of
soluble InlB or HGF probably occurs through a mechanism that
differs from that utilized by bacteria expressing surface-anchored InlB. Although the uptake of Listeria and cMet activated
by soluble ligands involves select components of clathrincoated pits (5), Listeria entry requires phosphatidylinositol
3-kinase activity (54), whereas the internalization of soluble
HGF or InlB does not depend on this kinase (3). Because soluble
InlB and HGF are internalized through identical pathways, we
used InlB as an initial ligand to examine the molecular control
of cMet endocytosis and then validated key findings using the
physiological ligand HGF.
Western analysis of cell lysates prepared from the stable cell
lines expressing wt or mutant cMet confirmed that treatment
with InlB for 15 min at 37 °C caused phosphorylation of wt and
the YF-cMet mutant on tyrosine residues 1234 and 1235 in the
activation loop but not on kinase-dead cMet (KinD-cMet) (Fig.
1A). Ubiquitination of wt cMet but not KinD-cMet was
increased in response to InlB. A low level of ubiqitinated YFcMet was detected under these conditions, consistent with the
direct association of Cbl to phosphotyrosine 1003 of cMet,
independently of Grb2 binding (14). Cbl phosphorylation was
not detected in unstimulated cells or in cells stably expressing
KinD-cMet after treatment with ligand (Fig. 1A). In keeping
with previous results (14, 36), cMet-mediated phosphorylation
of Cbl was reduced in cells expressing YF-cMet relative to cells
expressing wt cMet. This is consistent with a role for Grb2 in
recruiting Cbl to cMet via phosphotyrosine 1356. Surface biotinylation assays were used to confirm the cell surface expression
of wt and mutant cMet in each of the polyclonal cell lines (Fig.
1B). Cells were surface-biotinylated at 4 °C for 30 min using
NHS-SS-biotin. Cell lysates were then prepared, and biotinylated proteins were isolated by streptavidin pulldown and analyzed by Western blots. Comparable levels of wt and mutant
cMet were detected at the cell surface of the cell lines (Fig. 1B).
No cMet was detected in the parental null cells, consistent with
previous reports (49).
Using a GST pulldown assay, we verified that Grb2 bound to
wt cMet in response to InlB but not to YF-cMet or KinD-cMet
(Fig. 1C). No Grb2 binding was detected in the absence of
ligand, confirming that Grb2 binding to wt cMet was specific
and dependent on cMet autophosphorylation. Similarly, Gab1
phosphorylation in response to InlB was detected in null cells
expressing wt cMet but not in cells expressing the YF- or KinDcMet mutants (Fig. 1D), consistent with previous reports using
fibroblasts and HEK293 cells (35, 55). Together, these data con-
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FIGURE 2. siRNA-mediated Grb2 depletion inhibits InlB and HGF internalization. A, lysates from mock-transfected (Un) T47D/cMet cells or cells transfected with control (Con) or Grb2 siRNAs were examined by Western analysis
for Grb2, transferrin receptor (TfR), actin and cMet expression. B, mock-transfected T47D/cMet cells or cells transfected with the indicated siRNAs were
treated for 10 min at 37 °C with (⫹) or without (⫺) 100 ng/ml InlB. Cell
lysates were examined by Western analysis (IB) for expression of total
protein (cMet, Grb2, Cbl), phosphorylation IP cMet and Cbl (PY20), and
cMet ubiquitination (Ub). C, the relative amounts of internalized HGF, AlexaInlB, and Tfn (10 min at 37 °C) were quantified by confocal microscopy. Values
represent the mean fluorescence intensity ⫾ S.E. from four separate experiments and are expressed as a percentage of control values. D, T47D/cMet cells
transfected with control or Grb2-specific siRNAs were treated with 100 ng/ml
InlB for the indicated times at 37 °C, and surface cMet levels were quantified
by flow cytometry analysis as described in the legend to Fig. 1E.

that endogenous Grb2 is required for cMet uptake in different
cell types (supplemental Fig. S4). We confirmed the requirement for Grb2 in cMet internalization using flow cytometry. As
expected, we observed higher levels of surface cMet in Grb2depleted T47D/cMet cells relative to cells transiently transfected with a nonspecific control siRNA after receptor activation with InlB (Fig. 2D). Thus, loss of Grb2 led to a specific block
in HGF- and InlB-induced cMet internalization and not a general inhibition in clathrin-mediated endocytosis.
Interactions Downstream of Grb2 Recruitment Mediate cMet
Internalization—We used targeted dominant negative Grb2
mutants to determine whether the binding of Grb2 to cMet was
important for receptor endocytosis. Grb2 consists of a central
SH2 domain flanked by two SH3 domains. The central SH2
domain mediates Grb2 binding to phosphotyrosine 1356 in the
multisubstrate docking site of activated cMet and to the tyrosine-phosphorylated adaptor protein Shc. The SH3 domains of
Grb2 mediate its binding to critical signaling molecules including the adaptor Gab1 (56), cCbl (57, 58), and the large GTPase
dynamin (59). The mutations P49L and G203R in the N- and
C-terminal SH3 domains, respectively, (Fig. 3A), block these
interactions in a double Grb2 mutant (Grb2-mSH3). If Grb2 is
required for cMet internalization, we reasoned that in contrast
to wt Grb2, expression of a mutant expressing only the SH2
domain of Grb2 (Grb2-SH2) would function as a dominant negVOLUME 282 • NUMBER 23 • JUNE 8, 2007
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YF-cMet and KinD-cMet were routinely detected at each time
point. After an initial decrease in detected cell surface levels of
KinD-cMet and YF-cMet at 5 and 10 min, respectively, receptor
levels remained constant thereafter for up to 20 min of ligand
treatment. The initial reduction in the surface levels of cMet
could be the result of the constitutive internalization of cMet
consistent with our earlier studies (3) or steric hindrance of
antibody binding to cMet. We confirmed our flow cytometry
studies using Alexa-labeled InlB (Alexa-InlB) as a ligand to
examine the internalization of wt and mutant cMet by confocal
microscopy (supplemental Fig. S2). After incubation for 10 min
at 37 °C in media containing Alexa-InlB, internalized ligand
was detected with co-internalized Texas Red-labeled Tfn in
cells expressing wt cMet. Conversely, decreased levels of internalized InlB were detected in cells expressing KinD cMet or the
cMet mutant lacking a functional Gab1/Grb2 binding site (YF).
Rather, large spots of InlB fluorescence were detected on the
surface of cells expressing YF-cMet. Clathrin-mediated Tfn
uptake was unaffected in null cells expressing YF-cMet or
KinD-cMet, consistent with a specific block in cMet internalization rather than saturation of the clathrin-dependent endocytic machinery (supplemental Fig. S1). Thus, activation of the
cMet-tyrosine kinase activity and subsequent recruitment of
one or more of the proteins that are known to associate with
phosphotyrosines 1349 and 1356 are required for cMet internalization through clathrin-coated pits.
Grb2 Is Required for cMet Internalization—Our data indicating the dependence on phosphotyrosines 1349 and 1356 in the
multisubstrate docking region for cMet internalization raised
the possibility that the adaptors Grb2 and/or Gab1 could be
required for this process. To test this idea we used specific
siRNAs to deplete T47D/cMet cells of endogenous Grb2.
T47D/cMet cells are a human mammary epithelial cell line that
stably expresses human cMet on their surface and have been
extensively used on studies examining cMet signaling and
endocytosis in the past (3, 13, 14, 44). Endogenous Grb2 was
weakly detected by Western analysis in T47D/cMet cells transfected with Grb2-siRNAs (Fig. 2A). Conversely, comparable
levels of endogenous transferrin receptor, actin, and cMet were
observed in Grb2-depleted T47D/cMet cells as well as untransfected cells, and T47D/cMet cells transfected with a control
siRNA, demonstrating the specificity of the siRNA treatment.
Western analysis confirmed that siRNA-mediated depletion of
Grb2 did not reduce cMet phosphorylation in response to InlB
(10 min at 37 °C) (Fig. 2B). Conversely, cMet ubiquitination and
Cbl phosphorylation were reduced by Grb2 depletion. siRNAtreated cells were coincubated with Tfn and HGF or Alexa-InlB
for 10 min at 37 °C, and ligand internalization was measured by
confocal microscopy. cMet internalization in response to HGF
or InlB was reduced 51.3 ⫾ 4.85 and 74.4 ⫾ 2.87%, respectively,
in Grb2-depleted cells versus cells transfected with a control
siRNA (Fig. 2C). Comparable levels of co-internalized Tfn were
detected in control and Grb2-depleted T47D/cMet cells, indicating that loss of Grb2 led to a specific block in cMet internalization and not a general defect in clathrin-mediated endocytosis (Fig. 2C and supplemental Fig. S3). siRNA-mediated Grb2
depletion caused a comparable block in cMet endocytosis in
cMet null cells stably expressing wild type receptor, indicating
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ative mutant and block the binding of endogenous Grb2 to
cMet. Conversely, the SH3 double mutant (Grb2-mSH3) would
be unable to form productive complexes with downstream
effectors and, hence, function to impede cMet internalization
when expressed in cells. T47D/cMet cells were transfected with
wt or mutant Grb2 (Grb2-SH2, Grb2-mSH3) labeled at their C
termini with enhanced yellow fluorescent protein (EYFP) (Fig.
3A) to enable detection of the overexpressed proteins. The
presence of EYFP has been shown not to interfere with the
function of wt Grb2 or its mutants (22). Control Western analysis detected comparable levels of activated cMet in mocktransfected T47D/cMet cells and in cells expressing wt or
mutant Grb2 (supplemental Fig. S5) in response to InlB. In contrast to wt Grb2, expression of Grb2-mSH3 and to a lesser
extent Grb2-SH2 resulted in reduced extracellular signal-regulated kinase activation. The reduced activation of extracellular
signal-regulated kinase observed in cells expressing Grb2-SH2
was consistent with the lower transfection rate routinely
obtained using this construct (supplemental Fig. S5). The effect
of wt and mutant Grb2 on Alexa-InlB uptake in T47D/cMet
cells was quantified using confocal microscopy. After treatment
with Alexa-InlB for 10 min at 37 °C to stimulate cMet internalization, comparable levels of internalized ligand were
detected in control cells expressing EYFP only and in cells
expressing wt Grb2 (Fig. 3B and supplemental Fig. S6). Conversely, an 84 –90% decrease in the relative amount of internalized Alexa-InlB was detected in cells expressing Grb2-SH2 or
Grb2-mSH3, indicating that functional interactions downstream of Grb2 binding are important for cMet internalization.
JUNE 8, 2007 • VOLUME 282 • NUMBER 23

JOURNAL OF BIOLOGICAL CHEMISTRY

16769

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on September 24, 2019

FIGURE 3. Interactions downstream of Grb2 are involved in cMet internalization. A, schematic of EYFP-tagged wt or mutant (SH2, mSH3) Grb2 and
their binding properties. B, the relative amounts of internalized Alexa-InlB (10
min at 37 °C) in mock-transfected T47D/cMet cells and in cells expressing the
indicated EYFP-tagged Grb2 proteins were quantified by confocal microscopy. Values represent the mean fluorescence intensity ⫾ S.E. from four separate experiments and are expressed as a percentage of control (mock-transfected) values.

Cbl Ubiquitin Ligase Activity Is Required for cMet
Internalization—Consistent with our data demonstrating a
requirement for Grb2 in cMet internalization, we previously
reported that receptor endocytosis is impaired in cells overexpressing dominant negative dynamin (3). However, it remains
unclear which additional Grb2-mediated interactions are
required for the internalization of soluble InlB䡠cMet or
HGF䡠cMet complexes. Our initial studies focused on the E3
ubiquitin ligase Cbl for several reasons. Grb2-recuited Cbl
ubiquitin ligase activity has been implicated in the clathrin-dependent internalization of EGFR in response to EGF (17–21).
Grb2 has been shown to constitutively associate with the E3
ubiquitin ligase Cbl (60 – 62) and is recruited to cMet in
response to receptor activation (4, 14). Overexpression of a Cbl
mutant encompassing the N-terminal TKB and RING finger
domains has been reported to decrease cMet internalization,
possibly by blocking recruitment of CIN85-endophilin complexes to cMet (4). Although these studies demonstrated a
role for Cbl in cMet internalization, they focused only on the
adaptor functions of Cbl and did not examine the requirement for the ubiquitin ligase activity of Cbl for cMet internalization. Thus, the indirect recruitment of Cbl ubiquitin
ligase activity through Grb2 could contribute to Grb2 function in cMet endocytosis.
We tested the idea that the ubiquitin ligase activity of Cbl was
important for cMet internalization using confocal microscopy.
T47D/cMet cells were transfected with wt Cbl or Cbl mutants
defective in either ubiquitin ligase activity (70Z-Cbl) or binding
to phosphotyrosine 1003 (Cbl-G306E) (Fig. 4A). Previous studies have demonstrated that Cbl binds cMet and induces its
ubiquitination in response to HGF, whereas the ubiquitin
ligase-deficient mutant Cbl-70Z interacts with cMet but is
unable to induce receptor ubiquitination (4, 13, 14, 43). The
cells were allowed to co internalize Tfn with Alexa-InlB or HGF
for 10 min at 37 °C, and the relative amount of internalized
ligand was examined by confocal microscopy (supplemental
Fig. S7). cMet internalization was unaffected in mock-transfected control cells and in cells expressing wt Cbl or G306E, a
mutant unable to bind RTKs directly. However, in cells overexpressing the ubiquitin ligase-deficient mutant 70Z-Cbl, internalized HGF and Alexa-InlB staining was reduced to 33.5 ⫾ 2.4
and 50.4 ⫾ 2.6% of control levels, respectively (Fig. 4B). To
confirm the requirement of Cbl-mediated ubiquitination for
cMet internalization, we took advantage of well characterized
ubiquitin mutants that have altered conjugation and binding
properties (Fig. 4C). Cbl functions to covalently attach monoubiquitin to substrate proteins via the C-terminal glycine residues of ubiquitin. The ubiquitin mutant UbR lacks these glycine
residues important for substrate conjugation. However, UbR
retains the ability to interact with intracellular proteins harboring ubiquitin binding domains, including the ubiquitin-interacting motif. Thus, when expressed in cells, UbR functions to
block the interaction of ubiquitinated proteins with proteins
harboring a ubiquitin-interacting motif (18). Using confocal
microscopy, we examined the effect of transiently expressing
mutant ubiquitin (UbR) on cMet internalization in T47D/cMet
cells. UbR containing the double mutation L8A,I44A (UbRL8A,I44A) that blocks the interaction of UbR with ubiquitin
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FIGURE 4. Cbl ubiquitin ligase activity is involved in cMet internalization. A, schematic of hemagglutinin-tagged wt or mutant Cbl (70Z, G306E) and their binding properties. B, mock-transfected T47D/cMet
cells and T47D/cMet cells transiently expressing hemagglutinin-tagged wt or mutant Cbl were allowed to
internalize Alexa-InlB or 100 ng/ml HGF for 10 min at 37 °C, and the relative amounts of internalized
ligands were quantified by confocal microscopy. Internalized HGF was detected by staining cells with an
anti-HGF antibody. Values represent the mean fluorescence intensity ⫾ S.E. from four separate experiments and are expressed as a percentage of control (mock-transfected) values. C, schematic of cMyctagged wt ubiquitin (UbR GG), mutant ubiquitin (UbR) and the inactive variant UbR-L8A/I44A are shown.
D, the relative amounts of internalized Tfn and InlB in transfected T47D/cMet cells expressing the indicated constructs were quantified using confocal microscopy. Values represent the mean fluorescence
intensity ⫾ S.E. from four separate experiments and are expressed as a percentage of control (mocktransfected) values.
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FIGURE 5. Rescue of cMet internalization in Grb2-depleted cells using a Cbl-Grb2/SH2 chimeric protein.
A, schematic of EYFP-tagged mutant Grb2 (R86A) deficient in cMet binding, wild type Cbl (Cbl wt), Cbl fused to
the SH2 (cMet binding) domain of Grb2 or a mutant Grb2-SH2 domain (SH2/R86A). B, T47D/cMet cells were co
transfected with Grb2-specific siRNAs to deplete endogenous Grb2 and EYFP-tagged constructs as indicated.
The relative amounts of internalized Alexa-InlB and HGF were quantified by confocal microscopy. Values
represent the mean fluorescence intensity ⫾ S.E. from 4 separate experiments and are expressed as a percentage of control (mock-transfected) values.

interacting motifs was used as a
control (supplemental Fig. S8). As
shown in Fig. 4D, expression of UbR
reduced cMet internalization to
33.7 ⫾ 3.4% relative to mocktransfected control cells or cells
expressing the double mutant
UbR-L8A,I44A. Tfn uptake was
unaffected in cells expressing UbR
or UbR-L8A,I44A. This is the first
report indicating that the ubiquitin
ligase activity of Cbl is important for
cMet internalization in response to
soluble InlB as well as HGF.
Recruitment of Cbl through the
SH2 Domain of Grb2 Supports cMet
Internalization—Our data indicating a role for Grb2 and the ubiquitin
ligase activity of Cbl for the internalization of soluble ligand-cMet complexes suggested that the recruitment of a Grb2䡠Cbl complex could
be important for cMet internalization. To test this we transiently
transfected T47D/cMet siRNA-depleted of endogenous Grb2 with a
chimeric protein in which wt Cbl
was tagged with EYFP at its N terminus, and the SH2 domain of Grb2
was tagged at its C terminus (CblSH2) (22). In the absence of endogenous Grb2, Cbl recruitment to the
docking site of cMet would be predicted to occur via the Grb2-SH2
domain at the C terminus of the chimeric protein, thereby reversing the
inhibition of cMet endocytosis
imposed by Grb2 depletion. A second mutant chimeric protein deficient in cMet binding (Cbl-SH2/
R86A) (22) was used as a control
(Fig. 5A). In these studies, T47D/
cMet cells were co transfected with
Grb2-targeted siRNA and with CblSH2, Cbl-SH2/R86A, or mocktransfected cells as a control. The
cells were allowed to co internalize
Alexa-InlB and HGF for 10 min at
37 °C. Given the low double transfection rates routinely observed
using these constructs, we examined the relative amounts of internalized ligand using confocal
microscopy (Fig. 5B). Internalized
HGF was detected by co-staining
with an antibody specific for HGF.
Expression of the chimeric protein
Cbl-SH2 in Grb2-depleted cells
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FIGURE 6. siRNA-mediated Gab1 depletion does not inhibit InlB- and
HGF-induced cMet internalization. A, Western analysis of lysates from
mock-transfected (Un) and T47D/cMet cells transfected with control (Con) or
Gab1 siRNAs confirmed specific knock down of Gab1. B, T47D/cMet cells were
transfected with the indicated siRNAs after treatment with (⫹) or without (⫺)
100 ng/ml InlB for 10 min at 37 °C. Equal amounts of lysates were examined by
IP and Western analysis (IB) for total protein (cMet, Gab1, and Cbl), cMet phosphorylation (P-Met), ubiquitination (Ub), and Cbl phosphorylation (PY20) as
indicated. C, T47D/cMet cells transfected with control or Gab1-specific siRNAs
were treated with 100 ng/ml InlB for the indicated times at 37 °C, and surface
cMet levels were quantified by flow cytometry analysis.

molecules including Shc (29, 65). Surface biotinylation studies
confirmed that, like wt cMet, the mutant receptor NH-cMet
was expressed at the cell surface (Fig. 7A). GST pulldown assays
confirmed that recombinant Grb2 bound to wt cMet in
response to InlB. Conversely, Grb2 binding to NH-cMet was
inhibited under these conditions (Fig. 7B). cMet ubiquitination
and Cbl phosphorylation in response to InlB was detectable
in null cells expressing wt cMet but reduced in cells expressing the mutant NH-cMet (Fig. 7C). These data support the
conclusion that the direct binding of Grb2 to the docking site
of cMet is inhibited by the mutation N1358H. We next compared the internalization properties of NH-cMet with the
wild type receptor. Using Alexa-InlB to stimulate cMet
internalization (10 min, 37 °C), we confirmed that cMet
internalization was reduced in cMet null cells stably expressing NH-cMet but not in cMet null cells stably expressing wt
cMet by confocal microscopy (Fig. 7D). To confirm our confocal studies, we used flow cytometry analysis to compare the
internalization properties of wt and NH-cMet. Cells were incuJOURNAL OF BIOLOGICAL CHEMISTRY
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caused increased uptake of Alexa-InlB and HGF in Grb2-depleted cells compared with Grb2-depleted cells expressing
EYFP only. Conversely, expression of the chimeric protein deficient in cMet binding (Cbl-SH2/R86A) was not as effective at
rescuing cMet internalization in Grb2-depleted cells. Similarly,
overexpression of wt Cbl or Grb2/R86A (a Grb2 mutant deficient in cMet binding) did not reverse the inhibitory effect of
siRNA-mediated Grb2 depletion on cMet internalization.
Together, these data suggest that the major role of Grb2 in
cMet endocytosis is to recruit Cbl to the receptor.
The Signaling Adaptor Gab1 Is Not Required for cMet
Internalization—In addition to binding Cbl, Grb2 has been
shown to bind Gab1, an adaptor protein that mediates almost
all of the signaling cascades downstream from activated cMet
including phosphatidylinositol 3-kinase, c-Jun N-terminal
kinase, and extracellular signal-regulated kinase signaling (for
review, see Ref. 63). Gab1 is recruited to cMet by two mechanisms. The primary mechanism involves the indirect recruitment of Gab1 to cMet via Grb2 (35, 38). In addition, Gab1 can
bind directly to phosphotyrosine 1349 in the multisubstrate
docking site of cMet (64). To examine the importance of Gab1
in cMet internalization, a Gab1-specific siRNA was used to
deplete T47D/cMet cells of endogenous Gab1. Western analysis confirmed the specificity of the siRNA-mediated Gab1
knockdown in cells transfected with Gab1 but not a scrambled
control (Con) siRNA (Fig. 6A). Comparable levels of Cbl, actin,
Grb2, transferrin receptor, and cMet were detected in Gab1depleted cells as well as mock-transfected cells and cells transfected with a control siRNA. Western analysis confirmed that
siRNA depletion of Gab1 did not inhibit ligand-induced cMet
phosphorylation and ubiquitination or Cbl phosphorylation
(Fig. 6B). To examine the effect of Gab1 depletion on cMet
internalization, siRNA-treated cells were incubated with InlB
(100 ng/ml for 10 min at 37 °C) to activate cMet signaling, and
the relative amounts of residual cell surface cMet were measured using flow cytometry (Fig. 6C). Comparable levels of cell
surface cMet were detected in control and Gab1-depleted cells,
indicating that siRNA-mediated knockdown of Gab1 did not
inhibit cMet internalization in response to InlB. Confocal
microscopy studies confirmed that cMet internalization in
response to InlB or HGF was not decreased in Gab1 depleted
T47D/cMet cells or cells transfected with a control siRNA (data
not shown). Thus, loss of Gab1 does not block clathrin-mediated cMet internalization.
The Direct Binding of Grb2 to the Multisubstrate Docking Site
of cMet Promotes Receptor Endocytosis—A similar role for Grb2
and Cbl in EGFR internalization has been reported (17, 18, 21,
22), suggesting a general role for these proteins in RTK endocytosis. However, it is unclear whether Grb2 functions by
directly interacting with cMet at phosphotyrosine 1356. Alternatively, the ability of the adaptor Shc to recruit Grb2 indirectly
to cMet (56) may underlie the requirement for Grb2 in cMet
endocytosis. To distinguish between these possibilities, we generated a polyclonal cell line using cMet⫺/⫺ null cells expressing
moderate levels of the cMet mutant N1358H (NH-cMet).
N1358H is a well characterized mutation that specifically interferes with the direct binding of Grb2 to cMet with no measurable effect on the recruitment of other signaling or adaptor
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FIGURE 8. cMet internalization does not involve Shc. A, Western analysis of
lysates from mock-transfected (Un) and cMet null cells expressing wt cMet
transfected with control (Con) or Shc siRNAs for Shc, actin, and Grb2 confirmed specific knock down of the three family members of Shc. The asterisk
indicates a nonspecific immunoreactive band. B, cMet⫺/⫺ cells stably
expressing wt cMet were transfected with control or Shc specific siRNAs then
treated with 100 ng/ml InlB for the indicated times at 37 °C, and surface cMet
levels were quantified by flow cytometry analysis. Results are graphed as a
percentage of total surface cMet ⫾ S.E. before internalization.

bated in media containing 100 ng/ml InlB for increasing periods of
time at 37 °C and processed for flow cytometry. Under these conditions, the cell surface levels of NH-cMet remained unaltered
over the course of the experiment. Conversely, cell surface levels of
wt cMet decreased to 35.7 ⫾ 7.6% after treatment with 100 ng/ml
InlB for 20 min (Fig. 7E).
In contrast to our results above, Shc has been reported to regulate EGFR internalization (66), consistent with a role for the indirect recruitment of Grb2 for receptor internalization. To confirm
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DISCUSSION
It was unclear whether the regulatory mechanisms for clathrin-mediated endocytosis vary for different RTK subfamilies.
cMet and its oncogene TPR-Met are unique among RTKs in
that two key tyrosine residues in their C-terminal multisubstrate docking sites mediate all of the biological and transforming activities of these receptors. In this study we examined the
role of these tyrosines and their ability to bind specific signaling
proteins for the internalization of the proto-oncogene cMet.
Using variant forms of cMet with altered catalytic and binding
properties, we demonstrate that clathrin-dependent cMet
internalization is dependent on both the intrinsic kinase activity of the receptor and the recruitment of signaling molecules to
phosphotyrosines 1349 and 1356 in the unique multisubstrate
docking site of cMet. Depletion of Gab1 using siRNA did not
inhibit cMet internalization. However, the levels of Gab1 were
reduced but not abrogated in these studies, suggesting that low
levels of Gab1 could be sufficient to allow cMet internalization.
In a separate study we detected comparable levels of internalized cMet in mouse embryonic fibroblasts isolated from Gab1
null mice and a mouse embryonic fibroblast cell line isolated
from their wild type litter mates stably expressing wt cMet.3
Thus, we conclude that the recruitment of the signaling adaptor
Gab1 was dispensable for cMet internalization. Our studies are
the first to show a strict requirement for the ubiquitin ligase
3

N. Li, M. Lorinczi, K. Ireton, and L. A. Elferink, unpublished data.
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FIGURE 7. Direct Grb2 recruitment is required for cMet internalization. A, pulldown (PD) surface biotinylation assays confirmed that cMet null (⫺/⫺) cells stably express comparable levels of wt cMet or cMet-N1358H
(NH), a mutant deficient in Grb2 binding, at their surface. B, cMet null (⫺/⫺) cells stably expressing wt or mutant
cMet (NH) were treated with (⫹) or without (⫺) 100 ng/ml InlB for 10 min at 37 °C. Equal amounts of cell lysates
were incubated with recombinant GST-Grb2 and examined by Western analysis (IB). Grb2 binding to mutant
NH-cMet was inhibited in response to InlB treatment. C, total protein (cMet, Cbl), cMet ubiquitination (Ub), and
phosphorylation (P-Met) and Cbl phosphorylation (PY20) in response to InlB (⫹) were examined in lysates
prepared from cMet null (⫺/⫺) cells stably expressing wt or mutant cMet (NH) by IP and Western analysis. The
positions of molecular mass markers are indicated (kDa). D, confocal microscopy detected reduced levels of
internalized Alexa-InlB but not Tfn in cMet null (⫺/⫺) cells stably expressing mutant cMet (NH). Values represent the mean fluorescence intensity ⫾ S.E. from four separate experiments and are expressed as a percentage
of control (wt cMet) values. E, surface cMet levels on cells expressing wt or mutant (NH) cMet were determined
after treatment with 100 ng/ml InlB for the indicated times at 37 °C and quantified by flow cytometry analysis.
Results represented the mean fluorescent intensities normalized to untreated cells (0 min) from triplicate
experiments. Bars represent the means for data across three experiments with S.E.

that Shc is dispensable for cMet internalization, we used a siRNA approach
in cMet⫺/⫺ cells stably expressing wt
cMet. Western analysis detected
reduced levels of all three endogenous
Shc proteins measuring 46, 52, and 66
kDa in cells transfected with ShcsiRNA but not in mock-transfected
cells or cells transfected with a scrambled control siRNA (Fig. 8A). A nonspecific immunoreactive band was
routinely detected using Shc-specific
antibodies, consistent with previous
reports using other cell lines (67).
Comparable levels of actin and Grb2
were detected in Shc-depleted cells as
well as mock-transfected cells and
cells transfected with a control
siRNA. We quantified the effects of
siRNA-mediated Shc depletion on
cMet internalization using flow
cytometry analysis. Comparable levels of cell surface cMet were detected
in cells transfected with control or
Shc-siRNAs after treatment with 100
ng/ml InlB at all internalization times
(Fig. 8B), indicating that cMet internalization is not dependent on the
indirect recruitment of Grb2 through
the adaptor Shc.
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light of our observations, we propose that Grb2 bound directly
to cMet is indispensable for receptor endocytosis. In contrast to
cMet, Shc has been reported to play a role in EGF-induced
EGFR internalization (66, 72). EGF has been shown to promote
the formation of a complex between wild type Shc and the
adapter complex AP2 that is recruited to phosphotyrosine 1148
of the EGFR. Consistent with a role for Shc in EGFR endocytosis, the internalization rate constant of an EGFR truncation
mutant lacking the region encompassing phosphotyrosine
1148 was significantly slower than that observed for the wild
type receptor (73). Thus, the mode of Grb2 recruitment appears
to diverge for cMet versus EGFR internalization, suggesting
that distinct subsets of Grb2-mediated interactions are
involved in the clathrin-dependent internalization of different
RTKs.
The precise mechanism by which Cbl regulates cMet internalization and RTK endocytosis in general remains controversial. Cbl can be viewed as a bimodal molecule that functions as
an adaptor protein that physically links Cbl/cMet complexes to
the endocytic machinery (4) and as an E3 ubiquitin ligase to
ubiquitinate cMet (13, 14) and its associated endocytic components. Although Grb2 and Cbl ubiquitin ligase activity was
recently reported to be important for L. monocytogenes infection (5), these studies focused on the internalization of Listeria
expressing surface anchored InlB and not soluble InlB. Moreover, these studies did not examine cMet internalization
directly but instead monitored bacterial engulfment. A role for
Cbl as an adaptor that links HGF-activated cMet to the
endophillin-CIN85 complex (4) has been clearly demonstrated.
In these studies inhibition of complex formation using dominant interfering forms of endophilin, CIN85, or Cbl was sufficient to inhibit cMet internalization and enhance cMet signaling. However, these studies did not address the requirement for
Cbl ubiquitin ligase activity in this event or the mode of Cbl
recruitment to cMet. Our studies showing that expression of a
Cbl mutant deficient in ubiquitin ligase activity blocks cMet
internalization and that a Grb2䡠Cbl chimera rescues receptor
endocytosis in cells depleted of endogenous Grb2 are the first to
show a definitive role for Cbl ubiquitin ligase activity in this
process. Moreover, our studies indicate that Grb2 functions as
a critical intermediary for Cbl ubiquitin ligase activity in the
internalization of soluble InlB䡠cMet and HGF䡠cMet complexes.
Cbl has been shown to mediate ubiquitination of cMet in
response to HGF (43) in a process that involves the phosphotyrosine 1003 residue in the juxtamembrane region of cMet (13,
14, 42, 74). The observation that internalization of an ubiquitination-deficient Y1003F-cMet mutant is unaffected implies
that receptor ubiquitination may not be a critical determinant
for receptor internalization. Rather, Cbl-mediated ubiquitination of cMet via phosphotyrosine 1003 is important for degradation of the internalized receptor (13). Because the Y1003FcMet was weakly ubiquitinated, we cannot rule out the
possibility that different levels of, or sites of cMet ubiquitination contribute to distinct steps for cMet endocytic trafficking.
Alternatively, clathrin-dependent internalization and receptor
degradation may be regulated by the indirect recruitment of
Cbl via Grb2 to phosphotyrosine 1356 versus Cbl recruited
directly to phosphotyrosine 1003.
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activity of Cbl for the internalization of complexes formed
between cMet and two soluble receptor ligands, HGF and InlB.
Consistent with a role for Cbl ubiquitin ligase activity, overexpression of an ubiquitin mutant that could not be conjugated to
substrates yet retained the ability to bind to an ubiquitin interacting motif blocked ligand-induced cMet internalization.
Together, our results broaden the roles of Grb2 and Cbl ubiquitin ligase activity to cMet internalization, a receptor-tyrosine
kinase with unique structural and signaling characteristics.
A similar role for Grb2 has been reported for the EGFR.
EGFR internalization through clathrin-coated pits was specifically blocked in Grb2-depleted cells (17). The block in EGFR
internalization imposed by Grb2 depletion was rescued by transient expression of a Grb2䡠Cbl chimera (22). Overexpression of
Grb2-SH3 mutants deficient in binding downstream signaling
molecules inhibited the recruitment of EGFR to clathrincoated pits (18) and prevented the translocation of Grb2 with
activated EGFR into endocytic structures, presumably endocytic transport vesicles (48). In a separate study, overexpression
of Grb2 with inactivating point mutations in the SH3 domains
inhibited EGF-induced coated pit formation, with negligible
effects on the downstream activation of mitogen-activated protein kinase or phosphatidylinositol 3-kinase (19). Our studies
showing that Grb2-mediated internalization of cMet was
dependent on the ubiquitin ligase activity of Cbl are consistent
with several models for EGFR internalization in which the
Grb2䡠Cbl complex likely functions to couple distinct stages of
RTK endocytosis (20, 22, 68).
The multiadaptor Gab1 plays a critical role in cMet signaling
by providing a scaffold for the simultaneous activation of several downstream signaling cascades including the activation of
phosphatidylinositol 3-kinase, c-Jun N-terminal kinase, and
extracellular signal-regulated kinase signaling (for review, see
Ref. 63). Our data showing that the recruitment of Gab1 to
cMet is dispensable for receptor internalization are consistent
with our previous report that phosphatidylinositol 3-kinase signaling was not required for cMet endocytosis (3). cMet internalization was unaffected by overexpression of a dominant negative mutant for the p85 subunit of phosphatidylinositol
3-kinase. Similarly, no differences in the internalization properties of cMet were observed in T47D/cMet cells treated with
the phosphatidylinositol 3-kinase inhibitors LY294002 or wortmannin (3). Thus, although Gab1 likely regulates the intensity
and duration of cMet signaling, this does not appear to occur at
the level of receptor internalization.
The recruitment of Grb2 directly or indirectly via the adaptor
Shc to phosphotyrosine 1356 of cMet is essential for cell transformation and experimental metastases in response to oncogenic Met (69). The ability of Shc to form a stable complex with
Grb2 in response to HGF (56) and EGF (70, 71) suggested that
Grb2 recruited indirectly via Shc could regulate RTK endocytosis. Our data showing that cMet internalization was impaired
by the N1358H mutation suggested that the direct recruitment
of Grb2 to cMet rather than Grb2 recruited indirectly through
Shc mediates cMet internalization, since Shc binding is unaffected by the N1358H mutation (29, 65). Consistent with this
idea, siRNA-mediated Shc depletion did not interfere with
cMet internalization through clathrin-coated pits. Thus, in

cMet Uptake Requires Grb2 and Cbl Ubiquitin Ligase Activity
In conclusion our data demonstrate a strict requirement for a
specific subset of Grb2-mediated interactions for cMet internalization from the cell surface. The direct binding of Grb2 to
cMet is essential for receptor internalization. Moreover, endocytosis of soluble InlB䡠cMet and HGF䡠cMet complexes is
dependent on the E3 ubiquitin ligase activity of Cbl and does
not involve the Grb2 binding partner Gab1. Thus, Grb2 functions as an important intermediary for linking ligand-activated
cMet with the ubiquitin ligase activity of Cbl for receptor internalization via clathrin-coated pits.
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